SESSION TITLE: Tuesday Abstract Posters SESSION TYPE: Original Investigation Posters PRESENTED ON: 10/22/2019 01:00 PM - 02:00 PM PURPOSE: Tumor Lysis Syndrome has been associated with considerable morbidity and mortality, including a higher risk for prothrombotic states and Disseminated Intravascular Coagulation (DIC). These patients can also have thrombosis of the coronary arteries, venous thromboembolism (VTE) and pulmonary embolism (PE). The mechanism of VTE/PE in TLS is not exactly known but is thought to be related to the release of procoagulant factors from the tumor cells. However, the incidence of VTE/PE in TLS patients remains unclear. We hereby report the incidence of VTE/PE in TLS as well as in-hospital outcomes of patients with TLS presenting with VTE/PE compared to the general population. METHODS: The National Inpatient Sample (NIS) dataset was queried from 2012 to 2015 to identify the diagnosis of VTE/PE with the Clinical Classification Software code 118 among hospitalized patients. Among this patient population, we identified patients with TLS using the International Classification of Disease(ICD)- 9 code 277.88 as a coexisting medical condition. Categorical and continuous variables were tested using Chi-square test and Student t-test respectively. Multivariate regression was used for the analysis of primary outcomes of interest. RESULTS: Among 5,973,975 patients with VTE/PE only 3,795 patients were found to have TLS (0.0006%). The incidence of VTE/PE in TLS patients was found to be significantly greater than general population (11.17% vs. 4.66%, p<0.0001) after matching the two groups. Compared to the general population, patients with TLS were significantly younger (58.3 years vs. 64.1 years, p<0.001), were more likely to be male (62.32% vs 45.67%, p<0.001) and, non-white (31.92% vs. 28.11%,p=0.018). Patients with TLS were found to have a higher prevalence of fluids and electrolyte disorders (70.49% vs 32.6%, p<0.0001), anemia (32.41% vs. 25.47%, p<0.0001), pulmonary circulation disorders (11.07% vs. 6.81%, p<0.0001) and coagulopathy (11.07% vs 6.81%, p<0.0001). In terms of in-hospital outcomes, we found that the mean LOS (19.43 days vs. 6.92, p <0.0001) and cost ($2,40,887.00 vs $65,533.00, p<0.0001) were significantly increased in TLS patients presenting with VTE/PE. Furthermore, the in-hospital mortality rate was higher among patients with TLS with VTE/PE (23.58% vs 3.42%, p<0.0001). Also, patients with TLS who presented with VTE/PE were more likely to be readmitted (Readmit score: 27.98 vs. 20.25%, p<0.0001) compared to the general population. CONCLUSIONS: Patients with TLS have a higher incidence of VTE/PE compared to the general population and worse in-hospital outcomes including cost, LOS and mortality. CLINICAL IMPLICATIONS: Given that patients with TLS have significantly increased cost, LOS and mortality when presenting with VTE/PE, it is imperative that physicians are adept at recognizing this presentation in TLS patients in order to provide effective and timely intervention for better patient outcomes. DISCLOSURES: No relevant relationships by Kathir Balakumaran, source=Web Response No relevant relationships by Aakash Desai, source=Web Response No relevant relationships by Varun Tandon, source=Web Response